KAMADA Pharmaceutical (“Kamada”) conducted a Phase II/III clinical trial on the efficacy of proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema) which involved a multi-centre, randomized, double-blind, placebo-controlled study designed to evaluate Kamada’s formulation of human AAT to treat AATD in 168 patients. Inspiration Research Ltd. (“IRL”) was one of the centres involved in this trial.
IRL’s contribution to this study resulted in groundbreaking preliminary finding that “[participants in the] inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus placebo.” Patents in the study were given the option to extend their involvement to participate in a 50-week, open-label safety study. For further details of the study results please refer to KAMADA’s full Press Release.
IRL engages in a number of clinical trials with leading pharmaceutical companies to help in the advancement of novel therapies as well as patient education. If you are interested in participating in upcoming clinical trials, please connect with us through our Contact Page.